ArticleScience progress
Clinicopathological characteristics, one-year survival, and predictors among patients with soft tissue sarcoma: A retrospective cohort study at a tertiary referral center in Tanzania.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epithelioid Sarcoma of the Forearm in a 70-Year-Old Woman: A Case Report at a Referral Facility in Tanzania.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
ObjectiveSoft tissue sarcomas (STSs) are rare, heterogeneous tumors of mesenchymal origin that arise from muscle, fat, fibrous tissue, blood vessels, nerves, and connective tissue. They pose significant diagnostic and therapeutic challenges, and limited data exist on their epidemiology and outcomes in sub-Saharan Africa. This study assessed the clinicopathological characteristics and one-year survival of patients with STSs managed at a tertiary facility in Tanzania.MethodsA retrospective cohort review was conducted of medical records from January 2019 to April 2023. Data included patient demographics, tumor site, histological subtype, grade, stage at diagnosis, treatment modalities, and follow-up. Survival was estimated using Kaplan-Meier analysis, and Cox proportional hazards regression was applied to identify predictors of one-year survival.ResultsNinety-six cases were analyzed. Males constituted 54.2% of patients, and the majority (70.8%) were aged 15-64 years. Rhabdomyosarcoma was the most frequent histological type (34.4%), followed by sarcoma not otherwise specified (28.1%). Surgery was the predominant treatment modality. The overall one-year survival rate was 63.8% (95% CI: 48.0-71.7). Female sex (adjusted hazard ratio (HR): 3.36; 95% CI: 1.25-9.03;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.